ISM8207 for advanced solid tumors and B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug, ISM8207, for people with advanced solid tumors or certain B-cell lymphomas that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have an advanced solid tumor that has worsened after standard treatment, or a B-cell lymphoma that has come back or stopped responding to treatment.
- You are able to perform daily activities without significant help (ECOG score 0 or 1).
- You have not taken certain other drugs in the last 28 days or 5 half-lives (whichever is shorter).
- You agree to use effective birth control during the study and for 90 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing an investigational drug called SYS6077 to see if it is safe and tolerable for people with advanced solid tumors that have not responded to standard treatments. The goal is to find out if this drug is a safe option for patients who have run out of other choices.
This study tests a new drug (BMS-986482) alone or with other treatments for people with advanced solid tumors that haven't responded to standard therapies. The goal is to see if this drug can shrink tumors or slow their growth.
This study tests a new experimental drug (called SYS6051) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find out if the drug is safe and how well it works, and it might help control your cancer.
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
This study tests a new drug (SYS6005) that targets a protein called ROR1 on certain cancer cells. It is for people with advanced solid tumors or B-cell lymphomas that have stopped responding to other treatments.
This trial tests a new oral drug called ISM5939 for people with advanced or metastatic solid tumors. It aims to see if the drug is safe and helps shrink or control cancer when other treatments have stopped working.
Hear when a new Relapsed/Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.